Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT01984242 |
Title | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma |
Acronym | IMmotion150 |
Recruitment | Completed |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Hoffmann-La Roche |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ROU | POL | ITA | GBR | FRA | ESP | DEU | CZE |